Truist reiterates agilon health stock Hold rating at $112 target
Truist Securities has maintained its Hold rating for agilon health Inc (NYSE:AGL) with a price target of $112.00. The current stock price is $115.20, and the company is identified as one of the most undervalued stocks in the InvestingPro analysis. Truist highlights agilon health's focus on improving patient outcomes and reducing unnecessary utilization.
The company's strategy involves early detection of higher-risk patients, integration of clinical insights into primary care workflows, and the deployment of standardized clinical pathways for high-cost conditions. Truist observes that agilon health is methodical in developing and scaling its clinical programs. The key question for the firm remains the speed at which these improvements will lead to sustainable cost reductions and financial performance.
The analyst gained a better understanding of agilon health's infrastructure during the review. Five analysts have revised their earnings estimates upwards for the upcoming period, expecting the company to become profitable this year. A Pro Research Report is available for investors seeking deeper insights into agilon health's turnaround potential.
Agilon health reported stronger-than-anticipated third-quarter 2026 results, with adjusted earnings of $1.97 per share, surpassing the expected loss of $1.22 per share. Revenue also exceeded forecasts at $1.51 billion against the anticipated $1.46 billion. As a result, the company raised its full-year guidance. StoneX upgraded its price target for agilon health to $145 from $140 and maintained a Buy rating following the improved quarterly results and revised guidance.
The company's fiscal 2026 AEBITDA guidance expanded significantly to a range of $145 million to $155 million, nearly doubling the previous midpoint guidance of $85 million.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.